Stopping Semaglutide: What the Regain Data Shows

Two trials of Novo Nordisk's branded semaglutide, sold as Wegovy, studied stopping directly.

In STEP 4, every participant took branded semaglutide for 20 weeks, then half were switched to placebo without being told. Over the following 48 weeks, those who continued lost a further 7.9% of body weight on average, while those switched to placebo regained 6.9%.

In the STEP 1 extension, participants who stopped branded semaglutide after 68 weeks were followed for another year. They regained about two-thirds of the weight they had lost, and most of the improvements in blood pressure, blood sugar and cholesterol measures moved back toward where they had started.

Both trials included lifestyle counseling throughout. The regain happened anyway, which says more about the biology than about effort.

Semaglutide works on appetite: it slows how quickly the stomach empties and quiets the hunger signals that drive eating. When the medication is no longer there, those signals return. The lead author put it as taking your foot off the brake.

The authors suggest the medication may also leave some lasting effects on hormones and the brain's appetite control, which could help explain why, on average, people did not return all the way to their starting weight. But the main effect lasts only as long as the medication does.

That is why the authors, and the four US societies behind a 2025 joint nutrition advisory, describe obesity as a chronic condition. Regain after stopping is the expected course of a chronic condition when treatment ends, not evidence that someone did it wrong.

Weight is not the only thing that drifts. In the 2026 meta-analysis, studies that tracked HbA1c and systolic blood pressure after stopping found both rising again, and faster than weight. Around half of the HbA1c improvement had typically gone within two to three months, and most of the blood-pressure improvement within about three months, although HbA1c rarely returned all the way to where it started.

This matters if semaglutide was helping you with blood sugar, blood pressure or a fatty liver, not only with weight. Those benefits need their own plan after stopping, and the labs that showed them improving are the labs that will show whether they hold.

The meta-analysis does not say everyone ends up back where they started. On average, part of the loss persisted, and the authors suggest one reason: habits formed while appetite was quieter may outlast the medication. Here is what you can build while you are on it that does not leave when it does.

Habits. Smaller portions, protein first, regular meals, less alcohol, fewer ultra-processed foods. Months of eating this way while it is easy make it more likely to survive when it gets harder. What to eat on semaglutide covers the pattern.

Strength. Muscle you build or protect through resistance training is yours to keep, and it protects strength and function as you age. No study has yet measured whether weight regained after stopping returns as fat or as lean tissue; the 2026 authors list it as an open question. That uncertainty is a reason to train while you are on treatment, not after. Semaglutide, muscle and bone has the detail.

Labs and measurements. Your baseline panel and body-composition measurements, and the record of how they changed on treatment, are the reference point for everything after. If you stop, follow-up measurements show quickly whether weight, blood sugar and blood pressure are holding, rather than leaving you to notice months later.

A clinician who knows your history. Stopping is not the end of care. The program around the medication, from monitoring to nutrition and training, continues whether or not the medication does.

People stop for good reasons: cost, side effects that did not settle, reaching a goal, planning a pregnancy, or simply not wanting to take a medication indefinitely. All of those are legitimate, and none of them should be decided alone.

Stopping, or changing the plan, is decided with your clinician. That conversation looks at:

• Why you want to stop. If it is cost, the options may be different from what you assume; what semaglutide costs sets them out. If it is side effects, some can be managed.
• What the medication is doing for you beyond weight. If blood sugar, blood pressure or liver markers have improved, stopping affects those too, and they need a monitoring plan of their own.
• What is in place. How established the eating pattern, training and sleep are, and how your body composition has changed.
• What follow-up looks like. Which measurements, how soon after stopping, and what would prompt a change of plan.

If you are planning a pregnancy, tell your clinician as early as you can, because that changes the timing of the conversation.

We do not publish schedules for coming off semaglutide, and you should be wary of anyone who does. How the plan changes depends on your history, your goals and your numbers, and it is worked out with your clinician.

If you are comparing options rather than stopping altogether, the compounded vs Wegovy and semaglutide vs tirzepatide pages cover the alternatives.